Login/Register
- In general, US generics markets have two key challenges – tight competition, and pricing pressures. This impacts Sun Pharma as well. While the company can navigate these challenges, there could be an impact in the short term, in case of an issue. For instance, in the year FY18-19, the company had lost exclusivity for a drug in the US, thereby weakening its financials.
- While the financial performance is likely to be positive in the coming quarters, the valuation of Sun Pharma appears expensive. It trades at 106 times while its peer Divi’s Lab is trading at 45 times.
To read the RA disclaimer, please click here
Research Analyst: Bavadharini KS
Click here
Do you like this edition?
LEAVE A FEEDBACK
Disclaimer
All Topics
ⓒ 2023 Groww. All rights reserved, Built with ♥in India
Version - 4.2.2
More about Groww
+